Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.09 -0.21 (-0.74%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Novavax Stock’s Recent Surge and Future Potential
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Product Safety Supply Chain
Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?
Novavax will be ready for the new Covid-19 JN.1 variants in September, but NVAX stock is also undergoing a short squeeze. 
Via InvestorPlace
Exposures COVID-19
Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move
Novavax also said it's planning to launch a JN.1-focused Covid booster shot this fall. 
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
Pfizer Unusual Options Activity For June 03
Via Benzinga
Why Is Novavax (NVAX) Stock Up 20% Today?
Novavax continues to march higher in its recovery efforts, with its latest vaccine announcement lifting NVAX stock. 
Via InvestorPlace
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 
From Relay Therapeutics, Inc.
Via GlobeNewswire
What's Going On With Novavax Stock?
Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on. 
Via Benzinga
2 High-Yield Dividend Stocks to Buy Right Now
These two high-yield dividend stocks are top buys right now. 
Via The Motley Fool
Alphabet, Ventas, ASML And A Pharmaceutical Giant On CNBC's 'Final Trades'
Alphabet recently declared a $2 billion investment plan to establish its inaugural data center and Google Cloud region in Malaysia. 
Via Benzinga
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Investors shouldn't expect a big improvement in Pfizer's financials this year. 
Via The Motley Fool
7 Dividend Stocks to Invest In for a Lifetime of Income
Discover top dividend stocks to buy for 2024 to maximize profits and minimize risks in today’s investing environment. 
Via InvestorPlace
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial.  On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... 
Via Benzinga
The Income Investor’s Dream Team: 7 Sturdy Dividend Stocks Yielding 6%
Dividend stocks yielding 6% are at the higher end of risk but these shares won't fail income investors anytime soon. 
Via InvestorPlace
7 High-Yield Dividend Stocks That Work While You Sleep
Although it’s easy to focus only on compelling growth plays, investors should also branch out to high-yield dividend stocks. 
Via InvestorPlace
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Pfizer's list of patent-protected medicines is growing by leaps and bounds, but its stock price is under pressure. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come. 
Via The Motley Fool
Is Moderna Stock a Buy Now That It's a 2-Product Company?
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. 
Via The Motley Fool
7 Overlooked Stocks That Belong in Every Portfolio
Looking beyond the headlines creates an opportunity for investors who have the patience to seek must-own overlooked stocks. 
Via InvestorPlace
Moderna Investors Just Got Some Bullish News
This news could be worth billions... 
Via The Motley Fool
3 Discounted Stocks Poised for a Major Upswing
Explore discounted upswing stocks with strong financials and strategic advantages heading for a rebound soon. 
Via InvestorPlace
Blue-Chip Blunders: 7 Stocks to Sell as Management Missteps Mount
Sometimes top companies make bottom-shelf decisions; such is the case with these seven blue-chip stocks to sell. 
Via InvestorPlace
3 Stocks to Buy for Huge Income
All 3 of these stocks have a yield above 5%. 
Via The Motley Fool
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Pfizer Inc.
Via Business Wire
Is Pfizer the Best Dividend Stock for You?
Short-term expectation worries have elevated Pfizer's dividend yield. 
Via The Motley Fool
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer
Pfizer's Phase 3 CROWN trial results show Lorbrena significantly outperforms Xalkori in treating ALK-positive advanced NSCLC. 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.